Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.00.

Several brokerages recently weighed in on ESPR. Wall Street Zen cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Wednesday, October 8th.

Esperion Therapeutics Price Performance

ESPR opened at $2.66 on Friday. The business has a fifty day moving average price of $2.71 and a 200 day moving average price of $1.77. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $3.94. The stock has a market capitalization of $536.31 million, a price-to-earnings ratio of -5.32 and a beta of 0.92.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The firm had revenue of $87.31 million during the quarter, compared to analyst estimates of $78.33 million. On average, research analysts anticipate that Esperion Therapeutics will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ESPR. Nuveen LLC purchased a new position in shares of Esperion Therapeutics in the 1st quarter valued at about $4,446,000. Two Seas Capital LP boosted its holdings in Esperion Therapeutics by 43.6% in the second quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after purchasing an additional 3,024,104 shares in the last quarter. AIGH Capital Management LLC purchased a new position in Esperion Therapeutics in the third quarter valued at approximately $7,950,000. Marshall Wace LLP raised its holdings in Esperion Therapeutics by 46.2% during the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock worth $5,206,000 after purchasing an additional 1,679,294 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Esperion Therapeutics by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 945,491 shares of the biopharmaceutical company’s stock worth $2,506,000 after buying an additional 384,095 shares during the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.